Combination therapy of Eldecalcitol with Risedronate on Aromatase inhibitor treated post-operative Mammary carcinoma In the prevention of bone QUality and quantity Exacerbation randomized trial
Latest Information Update: 04 Jan 2021
Price :
$35 *
At a glance
- Drugs Eldecalcitol (Primary) ; Risedronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- Acronyms CERAMIQUE
- 29 Jul 2012 Planned End Date added to 1 May 2019 as reported by University Hospital Medical Information Network - Japan.
- 29 Jul 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 05 Jul 2012 New trial record